IL148968A0 - Neutral-cationic lipid for nucleic acid and drug delivery - Google Patents

Neutral-cationic lipid for nucleic acid and drug delivery

Info

Publication number
IL148968A0
IL148968A0 IL14896800A IL14896800A IL148968A0 IL 148968 A0 IL148968 A0 IL 148968A0 IL 14896800 A IL14896800 A IL 14896800A IL 14896800 A IL14896800 A IL 14896800A IL 148968 A0 IL148968 A0 IL 148968A0
Authority
IL
Israel
Prior art keywords
neutral
nucleic acid
drug delivery
cationic lipid
sup
Prior art date
Application number
IL14896800A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of IL148968A0 publication Critical patent/IL148968A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14896800A 1999-10-08 2000-10-10 Neutral-cationic lipid for nucleic acid and drug delivery IL148968A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15869399P 1999-10-08 1999-10-08
PCT/US2000/027974 WO2001026629A2 (en) 1999-10-08 2000-10-10 Neutral-cationic lipid for nucleic acid and drug delivery

Publications (1)

Publication Number Publication Date
IL148968A0 true IL148968A0 (en) 2002-11-10

Family

ID=22569279

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14896800A IL148968A0 (en) 1999-10-08 2000-10-10 Neutral-cationic lipid for nucleic acid and drug delivery

Country Status (17)

Country Link
US (2) US6974589B1 (ko)
EP (1) EP1223916B1 (ko)
JP (1) JP2003511405A (ko)
KR (1) KR100723852B1 (ko)
CN (2) CN1915968A (ko)
AT (1) ATE276744T1 (ko)
AU (2) AU7868400A (ko)
CA (1) CA2386164A1 (ko)
DE (1) DE60014133T2 (ko)
DK (1) DK1223916T3 (ko)
ES (1) ES2226932T3 (ko)
HU (1) HUP0203117A3 (ko)
IL (1) IL148968A0 (ko)
MX (1) MXPA02002899A (ko)
NO (1) NO20021615L (ko)
WO (2) WO2001026625A2 (ko)
ZA (1) ZA200202726B (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE340592T1 (de) 1999-04-23 2006-10-15 Alza Corp Konjugate enthaltend eine spaltbare bindung zur anwendung in einem liposom
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US20040197390A1 (en) * 2001-05-29 2004-10-07 Shi-Kun Huang Neutral-cationic lipid for systemic delivery of factor VIII gene
WO2001026625A2 (en) * 1999-10-08 2001-04-19 Alza Corp Neutral-cationic lipid for nucleic acid and drug delivery
DE10207177A1 (de) * 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
MXPA06012722A (es) * 2004-05-05 2007-02-14 Atugen Ag Lipidos, complejos de lipido y su uso.
EP1935434A1 (en) * 2006-12-19 2008-06-25 Novosom AG Construction and use of transfection enhancer elements
TWI486169B (zh) * 2007-04-20 2015-06-01 Sigma Tau Rare Diseases S A 酵素性抗癌療法
CN101475503B (zh) * 2008-12-15 2012-02-15 山东大学 一种新型阳离子类脂及其制备方法和应用
EP2532649B1 (en) * 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
RU2013154295A (ru) 2011-06-08 2015-07-20 Шир Хьюман Дженетик Терапис, Инк. КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК
KR101480055B1 (ko) * 2012-04-04 2015-01-09 주식회사 삼양바이오팜 음이온성 약물 전달체의 제조 방법
CN105585598B (zh) * 2014-10-20 2019-02-19 湖南师范大学 甘露糖衍生物阳离子脂质体纳米颗粒的制备方法
EP3362563A1 (en) * 2015-10-14 2018-08-22 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for liposomal formulation
CN107200841B (zh) * 2016-03-17 2019-02-01 华东师范大学 一种培化二酰甘油的合成方法
JP7132911B2 (ja) 2016-09-16 2022-09-07 バイオ-パス ホールディングス, インコーポレイテッド リポソームアンチセンスオリゴヌクレオチドとの併用療法
IL269608B2 (en) 2017-04-19 2024-06-01 Bio Path Holdings Inc Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease
CN110709065B (zh) * 2017-04-19 2023-02-10 Apa先进技术有限公司 融合脂质体、组合物、试剂盒及其治疗癌症的用途
EP3612160A4 (en) 2017-04-19 2021-01-20 Bio-Path Holdings, Inc. P-ETHOXY NUCLEIC ACIDS FOR BCL2 INHIBITION
KR20250150267A (ko) 2024-04-11 2025-10-20 한국과학기술연구원 아연 및 디피콜릴아민을 포함하는 핵산 결합용 양쪽성 지질 화합물 및 이를 포함하는 지질 나노입자 조성물
CN119792316B (zh) * 2025-03-14 2025-12-09 中国医学科学院医学生物学研究所 磷脂酸在制备预防和/或治疗广谱病毒感染药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5965434A (en) * 1994-12-29 1999-10-12 Wolff; Jon A. Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds
DE19521412A1 (de) * 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
WO2000030444A1 (en) * 1998-11-25 2000-06-02 Vanderbilt University Cationic liposomes for gene transfer
WO2001026625A2 (en) * 1999-10-08 2001-04-19 Alza Corp Neutral-cationic lipid for nucleic acid and drug delivery

Also Published As

Publication number Publication date
HUP0203117A2 (hu) 2003-01-28
DK1223916T3 (da) 2005-01-31
KR20020063875A (ko) 2002-08-05
HUP0203117A3 (en) 2005-06-28
EP1223916A2 (en) 2002-07-24
DE60014133D1 (de) 2004-10-28
US20050260261A1 (en) 2005-11-24
ATE276744T1 (de) 2004-10-15
AU778817B2 (en) 2004-12-23
WO2001026629A2 (en) 2001-04-19
WO2001026629A3 (en) 2002-05-10
ES2226932T3 (es) 2005-04-01
MXPA02002899A (es) 2002-10-23
JP2003511405A (ja) 2003-03-25
CA2386164A1 (en) 2001-04-19
NO20021615D0 (no) 2002-04-05
US6974589B1 (en) 2005-12-13
CN1915968A (zh) 2007-02-21
CN1378536A (zh) 2002-11-06
KR100723852B1 (ko) 2007-05-31
AU8006400A (en) 2001-04-23
ZA200202726B (en) 2003-06-25
DE60014133T2 (de) 2005-02-03
WO2001026625A2 (en) 2001-04-19
AU7868400A (en) 2001-04-23
NO20021615L (no) 2002-04-05
EP1223916B1 (en) 2004-09-22

Similar Documents

Publication Publication Date Title
IL148968A0 (en) Neutral-cationic lipid for nucleic acid and drug delivery
ATE178067T1 (de) Camptothecinderivate
AU528275B2 (en) Imidazole derivatives
IE812460L (en) Substituted azabicyclo-octane-carboxylic acids
EP0488513A3 (en) Use of dioxabicyclo [3.3.0]octane derivatives for the manufacture of a medicament for inhibiting the metabolism of cholesterol.
WO1999020639A3 (en) NOVEL 3,6-HEMIKETALS FROM THE CLASS OF 9a-AZALIDES
WO2002007677A3 (en) Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
MY129935A (en) Dihydropyridine derivatives useful in antitumor therapy
WO2003051848A3 (en) Imidazolidineacetic acid derivatives
NZ521201A (en) Method for the preparation of citalopram
EP0335979A4 (en) Thienopyrimidine derivatives
DE60237323D1 (de) Zusammensetzung enthaltend Ferrocen-Derivate und Treibstoff diese enthaltend
WO2003075928A3 (en) Stable pharmaceutical compositions
PL322069A1 (en) Arginin analoques exhibiting inhibiting activity in respect to synthase no
EP0204148A3 (en) [1,4]Benzodioxin and [1,4]benzoxazine derivatives
PE68299A1 (es) 1,2,3,4-tetrahidroisoquinolinas terapeuticas
SE1214315T3 (ko)
CA2338776A1 (en) Novel c-2 s/o- and s/n formaldehyde acetal derivatives of carbapenem-3-carboxylic acids and their use as antibiotics and .beta.-lactamase inhibitors
GB2321459A (en) Synthesis of carboxylic acid derivatives
AU3181600A (en) 2'-substituted rna preparation
IL106080A (en) Pharmaceutical compositions containing amidinoalkane-1, 1-bisphosphonic acids and some such novel compounds
IT1276161B1 (it) Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi
AU7759501A (en) Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same
DE60007984D1 (de) Antioxidantien, verfahren zu ihrer herstellung und ihre verwendungen
EP0218195A3 (en) Bis(dibenzo[b,d]pyranyloxy)propanes